The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma.
John A. Thompson
Research Funding - Seattle Genetics; Seattle Genetics
Andres Forero
Research Funding - Seattle Genetics
Elisabeth I. Heath
Research Funding - Seattle Genetics
Sumanta Kumar Pal
Research Funding - Seattle Genetics
Stephen Maxted Ansell
Research Funding - Seattle Genetics
Jeffrey R. Infante
Research Funding - Seattle Genetics
Sven De Vos
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
Paul A. Hamlin
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
Nancy Cherry Whiting
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Baiteng Zhao
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Nizar M. Tannir
Research Funding - Seattle Genetics